Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National surgical adjuvant breast and bowel project B-18.J Clin Oncol. 1997; 15: 2483-2493
- Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902.J Clin Oncol. 2001; 19: 4224-4237
- Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European cooperative trial in operable Breast Cancer.J Clin Oncol. 2009; 27: 2474-2481
- Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.JAMA. 2013; 310: 1455-1461
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study.Lancet Oncol. 2013; 14: 609-618
- Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study.J Clin Oncol. 2015; 33: 258-264
- Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.Breast Cancer Res Treat. 2019; 173: 343-352
- Trastuzumab emtansine for residual invasive HER2-positive breast cancer.N Engl J Med. 2019; 380: 617-628
- Adjuvant capecitabine for breast cancer after preoperative chemotherapy.N Engl J Med. 2017; 376: 2147-2159
- Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer.N Engl J Med. 2018; 379: 111-121
- Abstract GS3-00: First results from a phase III randomized clinical trial of standard adjuvant endocrine therapy (ET) +/- chemotherapy (CT) in patients (pts) with 1-3 positive nodes, hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25: SWOG S1007 (RxPonder).Cancer Res. 2021; 81 (GS3-00-GS3-00)
- Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.Cancer. 2007; 110: 244-254
- Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.Ann Oncol. 2012; 23: 3069-3074
- Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis.JAMA Oncol. 2016; 2: 1477-1486
- Breast cancer in elderly women: a cancer research Campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The elderly breast cancer working party.Br J Surg. 1991; 78: 591-594
- Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable breast cancer.Br J Surg. 2004; 91: 699-704
- Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The G.R.E.T.A. Trial. Group for Research on Endocrine Therapy in the Elderly.Anticancer Res. 1994; 14: 2197-2200
- Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial.Ann Oncol. 2003; 14: 414-420
- Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.Ann Oncol. 2001; 12: 1527-1532
- Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.J Clin Oncol. 2005; 23: 5108-5116
- Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial.Cancer. 2006; 106: 2095-2103
- Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.J Clin Oncol. 2011; 29: 2342-2349
- Role of magnetic resonance imaging in detection of pathologic complete remission in breast cancer patients treated with neoadjuvant chemotherapy: a meta-analysis.Clin Breast Cancer. 2017; 17: 245-255
- MRI evaluation of residual tumor size after neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy.Eur J Radiol. 2012; 81: 2148-2153
- Impact of residual nodal disease burden on technical outcomes of sentinel lymph node biopsy for node-positive (cN1) breast cancer patients treated with neoadjuvant chemotherapy.Ann Surg Oncol. 2019; 26: 3846-3855
- How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? results of a prospective study.Ann Surg Oncol. 2016; 23: 3467-3474
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.Lancet. 2014; 384: 164-172
- Patterns of Axillary management in stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach.Ann Surg Oncol. 2019; 26: 4326-4336
- Gauging the efficacy of neoadjuvant endocrine therapy in breast cancer patients with known axillary disease.J Surg Oncol. 2020; 122: 619-622https://doi.org/10.1002/jso.26047
- How effective is neoadjuvant endocrine therapy (NET) in downstaging the axilla and achieving breast-conserving surgery?.Ann Surg Oncol. 2020; 27: 4702-4710
- Surgical management of axilla following neoadjuvant endocrine therapy.Ann Surg Oncol. 2021; 28: 8729-8739
- Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.Breast Cancer Res. 2020; 22: 54
- Axillary ultrasound after neoadjuvant chemotherapy and its impact on sentinel lymph node surgery: results from the american college of surgeons oncology group Z1071 Trial (Alliance).J Clin Oncol. 2015; 33: 3386-3393
- Axillary lymph node ultrasound following neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: results from the SN FNAC Study.Ann Surg Oncol. 2019; 26: 4337-4345
- Clinical practice guidelines in oncology. breast cancer (Version 8.2021).(Available at:) (Accessed March 15, 2022)
- Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer.NPJ Breast Cancer. 2020; 6: 35
- Axillary management after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer.Ann Surg Oncol. 2021; 28: 1358-1367https://doi.org/10.1245/s10434-020-09073-6
- Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients.Breast Cancer Res Treat. 2021; 186: 327-342
- Is the 21-gene recurrence score on core needle biopsy equivalent to surgical specimen in early-stage breast cancer? A comparison of gene expression between paired core needle biopsy and surgical specimens.Ann Surg Oncol. 2021; 28: 5588-5596
- Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.J Surg Oncol. 2017; 115: 917-923
- Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.Breast Cancer Res Treat. 2019; 173: 123-133
- Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.Lancet Oncol. 2012; 13: 345-352
- Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.Clin Cancer Res. 2005; 11: 951s-8s
- Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.J Natl Cancer Inst. 2008; 100: 1380-1388
Article info
Publication history
Published online: July 20, 2022
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
